Skip to main content
Back to Trials
NCT07482384NARecruiting

Supporting Health Including Endocrine Treatment for Long Duration

Dana-Farber Cancer Institute

Start Date

8/4/2026

Completion Date

5/1/2027

Summary

This research is being done to pilot an intervention which aims to test a new web- and mobile application ("app")-based supportive care tool (SHIELD portal) and to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease long-term endocrine treatment.

Detailed Description

This research study is a single-arm intervention pilot study to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease prescribed long-term endocrine treatment. The SHIELD portal is designed to help monitor the frequency and variation in cancer and treatment-related issues and to share self-management information and resources to those interested in particular issues or who indicate a specific concern, symptom or side effect on measures designed to assess and track salient symptoms. Research study procedures include screening for eligibility, in-clinic and virtual approaches for recruitment, gaining access and using the SHIELD web- and mobile app-based supportive care portal, and completing of survey assessments on the SHIELD portal. Participation in this research study is expected to last 3 months. It is expected that 30 people will take part in this research study.

Eligibility Criteria

Age Range: 18 years to 49 years

Inclusion criteria Participants will be eligible if they meet the following eligibility criteria: * Female * Age 18-49 years at diagnosis of a stage 0-IIIa, HR+ breast cancer * Premenopausal * In active treatment (including long-term endocrine therapy) at the time of enrollment * Able to speak, understand and read English * Access to a US-based mobile phone number * Cognitively able to complete study requirements * Ability to access medical records from treating hospital (DFCI) * Willing to provide cell phone number and/or email address and willing to receive email, mobile push notifications, and/or text messages from the study team Exclusion criteria Participants will be ineligible if they meet any of the following criteria: * Individuals under age 18 or over age 50 at initial breast cancer diagnosis * Stage IV or metastatic breast cancer * Pregnant patients * Individuals who do not have a US mobile phone number * Males with breast cancer are not being recruited to this protocol. In the adolescent and young adult (AYA) age group, only a miniscule proportion of breast cancers occur in males. Additionally, this pilot focuses on breast cancer treatment utilizing OFS and ET, both of which do not apply to males. For this reason, the SHIELD portal intervention materials have been targeted for young women.

Interventions

BEHAVIORAL

SHIELD portal

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Breast CancerBreast Cancer - FemaleBreast CarcinomaER Positive Breast CancerPR-Positive Breast Cancer

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts 02215

United States